Cargando…

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

BACKGROUND: Neutralizing factor VIII (FVIII) antibodies are a major complication in hemophilia A. Antihemophilic factor VIII (recombinant), porcine sequence (rpFVIII; susoctocog alfa; Baxalta US Inc., a Takeda company) has low cross‐reactivity to anti‐human FVIII antibodies and can provide functiona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Négrier, Claude, Oldenburg, Johannes, Kenet, Gili, Meeks, Shannon L., Bordet, Jean‐Claude, Müller, Jens, Le Quellec, Sandra, Turecek, Peter L., Tripkovic, Nikola, Dargaud, Yesim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207117/ https://www.ncbi.nlm.nih.gov/pubmed/35765670 http://dx.doi.org/10.1002/rth2.12731

Ejemplares similares

Thrombin generation and implications for hemophilia therapies: A narrative review
por: Sidonio, Robert F., et al.
Publicado: (2022)

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
por: Dargaud, Yesim, et al.
Publicado: (2021)

Why patients with THBD c.1611C>A (p.Cys537X) nonsense mutation have high levels of soluble thrombomodulin?
por: Jourdy, Yohann, et al.
Publicado: (2017)

Clinical Utility of Subcutaneous Factor VIII Replacement Therapies in Hemophilia A: A Review of the Evidence
por: Dargaud, Yesim, et al.
Publicado: (2021)

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
por: Doshi, Bhavya S., et al.
Publicado: (2012)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021)

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults
por: Konkle, Barbara A., et al.
Publicado: (2023)

Recombinant porcine factor VIII in acquired hemophilia A: Experience from two patients and literature review
por: Hayden, Alexander, et al.
Publicado: (2022)

Acquired Hemophilia A Treated with Recombinant Porcine Factor VIII: Case Report and Literature Review on Its Efficacy
por: Borro, Matteo, et al.
Publicado: (2023)

Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy
por: Meeks, Shannon L., et al.
Publicado: (2020)

B cell–activating factor modulates the factor VIII immune response in hemophilia A
por: Doshi, Bhavya S., et al.
Publicado: (2021)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice
por: Lai, Jesse D., et al.
Publicado: (2018)

Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?
por: Giffard-Quillon, Lorine, et al.
Publicado: (2020)

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits
por: Schiavoni, Mario, et al.
Publicado: (2019)

Multiple criteria decision analysis for therapeutic innovations in a hemophilia care center: A pilot study of the organizational impact of innovation in hemophilia care management
por: Beny, Karen, et al.
Publicado: (2022)

Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
por: Jiménez‐Yuste, Víctor, et al.
Publicado: (2022)

Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors
por: Brackmann, Hans H., et al.
Publicado: (2020)

Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature
por: Lalezari, Shadan, et al.
Publicado: (2021)

The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making
por: Wang, Michael, et al.
Publicado: (2022)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
por: Le Quellec, Sandra
Publicado: (2020)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner
por: Batsuli, Glaivy, et al.
Publicado: (2023)

Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy
por: McCall, Michael, et al.
Publicado: (2019)

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia
por: Monahan, Paul E., et al.
Publicado: (2021)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
por: Ettingshausen, Carmen Escuriola, et al.
Publicado: (2023)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015)

Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A
por: Bachelet, Delphine, et al.
Publicado: (2019)

Patients’ Perception of the Impact of Innovation on Hemophilia Care Management Organization: A Qualitative Study Protocol (INNOVHEMO Study)
por: Beny, Karen, et al.
Publicado: (2021)

Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review
por: Verhagen, Marieke J. A., et al.
Publicado: (2022)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6qurd2b3erljokr1ua03lp2hmk